← Oncology Approval Tracker

FDA DECISION ·

Monjuvi

tafasitamab-cxix · Incyte

FDA approvalNew or expanded indicationFollicular lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

With lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma.

LAMPGEN ANALYSIS

Why it matters

The three-drug regimen adds a CD19-directed antibody to rituximab and lenalidomide in recurrent disease.

What research teams should watch

Prepare a joint infusion and oral-drug calendar and document infection and cytopenia assessments across components.

PRIMARY RECORDS

Sources